Shots:

• The 1st patient has been vaccinated in a P- II/III D7220C00001 trial assessing the safety & immunogenicity of AZD2816 in 2-250 adults aged >18yrs. with COVID-19 in both previously vaccinated & unvaccinated adults
• AZD2816 will be given to patients who have previously fully vaccinated with 2 doses of Vaxzevria at least 3mos. after the last injection. In unvaccinated patients- AZD2816 will give in 2 doses 4-12wks. apart- or as a 2nd dose following the 1st dose of Vaxzevria @4wks. apart
• The initial data of the study is expected in 2021. The data will be submitted to regulators for assessment as a next-generation booster vaccine and through an expedited regulatory pathway

Ref: AstraZeneca | Image: Business Standard